Lomitapide, un inhibidor de la transferencia de triglicéridos microsómicos en la hipercolesterolemia familiar homocigótica: una revisión sistemática y un metanálisis de la eficacia y la seguridad
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.La lomitapida reduce significativamente el colesterol LDL y los lípidos aterogénicos en pacientes con hipercolesterolemia familiar homocigótica (HOFH). Este inhibidor de la transferencia de triglicéridos microsomal muestra un perfil de seguridad aceptable, lo que apoya su uso como terapia adyuvante.
Área De La Ciencia
- Medicina cardiovascular
- La genética
- Farmacología
Sus Antecedentes
- La hipercolesterolemia familiar homocigótica (HoFH) es un trastorno genético grave que causa enfermedades cardiovasculares tempranas debido al alto nivel de LDL-C.
- Lomitapide, un inhibidor de la MTP, ofrece un nuevo enfoque de tratamiento mediante la reducción de LDL-C independientemente de la función del receptor de LDL.
Objetivo Del Estudio
- Revisar sistemáticamente y meta- analizar la eficacia y seguridad de lomitapida en pacientes con HoFH.
- Evaluar el impacto de lomitapida en los perfiles lipídicos y los eventos adversos en esta rara afección genética.
Principales Métodos
- Se realizó una búsqueda exhaustiva de literatura en PubMed, Scopus y Web of Science hasta marzo de 2025.
- Se incluyeron estudios observacionales y ensayos clínicos que informaron sobre cambios en los lípidos y la seguridad en pacientes con HoFH tratados con lomitapida.
- Se utilizaron modelos de efectos aleatorios para la agrupación de resultados, y la heterogeneidad se evaluó a través de la estadística I2.
Principales Resultados
- Se analizaron ocho estudios en los que participaron 209 pacientes adultos y pediátricos.
- La lomitapida redujo significativamente el colesterol LDL (49,27%), el colesterol total (46,05%) y la apolipoproteína B (51,01%).
- También se observaron reducciones en los triglicéridos y en el VLDL-C; el HDL-C se mantuvo estable. Las reacciones adversas gastrointestinales fueron frecuentes, llevando a una tasa de interrupción del 14%.
Conclusiones
- La lomitapida demuestra una eficacia significativa en la reducción de los lípidos aterógenos en pacientes con HHO.
- El medicamento presenta un perfil de seguridad aceptable, lo que respalda su papel como terapia complementaria.
- Se recomiendan ensayos controlados aleatorios adicionales para confirmar la seguridad y eficacia a largo plazo.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...